Market Research on Metastatic Melanoma - Pipeline Review, H2 2016

Metastatic Melanoma - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Metastatic Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Melanoma and features dormant and discontinued projects.

To access full report with TOC, please visit Metastatic Melanoma - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
- The report reviews pipeline therapeutics for Metastatic Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Metastatic Melanoma therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Metastatic Melanoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
- Identify potential new clients or partners in the target demographic
- Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

AB Science SA AbbVie Inc Adaptimmune Therapeutics Plc Affichem SA Agalimmune Ltd AGV Discovery, SAS Altor BioScience Corporation Amgen Inc. Angimmune LLC Apexigen, Inc. Arisaph Pharmaceuticals, Inc. Array BioPharma Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc Basilea Pharmaceutica Ltd. Bellicum Pharmaceuticals, Inc. BerGenBio AS Bioncotech Therapeutics SL Bionomics Limited Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Calithera Biosciences, Inc. Cellceutix Corporation Celldex Therapeutics, Inc. Cortice Biosciences, Inc. Delcath Systems, Inc. Digna Biotech, S.L. Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Ensol Biosciences Inc. F. Hoffmann-La Roche Ltd. Galapagos NV Galectin Therapeutics, Inc. GlaxoSmithKline Plc Idera Pharmaceuticals, Inc. Ignyta, Inc. Immune Design Corp. Immunocore Limited ImmuRx, Inc. Incyte Corporation Infinity Pharmaceuticals, Inc. IO Biotech ApS Lentigen Technology, Inc. Life Science Pharmaceuticals, Incorporated Lipotek Pty Ltd. MacroGenics, Inc. MedImmune, LLC Medivation, Inc. MELEMA Pharma GmbH Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals Inc Modulate Therapeutics, Inc. Moleculin Biotech Inc Morphotek, Inc. NewLink Genetics Corporation Novartis AG Omeros Corporation Oncolytics Biotech Inc. OncoSec Medical Incorporated Onxeo SA Pfizer Inc. Pharmis Biofarmaceutica, Lda. Philogen S.p.A. PinCell srl Plexxikon Inc. Polaris Pharmaceuticals, Inc. Prima BioMed Ltd. Provectus Biopharmaceuticals, Inc. Provenance Biopharmaceuticals Corp. Reata Pharmaceuticals, Inc. Recepta Biopharma S.A. RXi Pharmaceuticals Corporation Scancell Holdings Plc Sillajen Biotherapeutics SolaranRx, Inc. Syndax Pharmaceuticals Inc Takara Bio Inc. TC BioPharm Limited Tikcro Technologies, Ltd. Ultimovacs AS

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###